Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Darren McGuire

Cardiovascular Disease Dallas, TX Medical Doctor

NPI 1336106715 CMS profile 15139

5323 Harry Hines Blvd, Dallas, TX 75390

Open in the dashboard

General payments

$1,190,560

532 records reported · program years 2019–2025

Research payments

$247,115

Paid to them · 92 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$122,633 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Darren McGuire of Dallas, TX is reported in the CMS Open Payments database as having received $1,190,560 across 532 general payments and $247,115 in research payments paid to them. Separately, studies naming them as principal investigator received $122,633 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89,727 48
2025 Research $21,924 7
2024 General $162,597 61
2024 Research $49,482 8
2023 General $235,073 83
2023 Research $51,253 8
2022 General $127,164 61
2022 Research $44,733 26
2021 General $97,433 40
2021 Research $44,575 30
2020 General $157,264 66
2020 Research $22,823 12
2019 General $321,302 173
2019 Research $12,325 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darren McGuire
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Darren McGuire were reported at $89,727. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Darren McGuire Cardiovascular Disease median Middle half National median
2019 $321,302 $450 $127–$1,392 $163
2020 $157,264 $242 $77–$751 $114
2021 $97,433 $335 $101–$1,037 $132
2022 $127,164 $395 $121–$1,211 $149
2023 $235,073 $443 $136–$1,283 $160
2024 $162,597 $450 $136–$1,323 $164
2025 $89,727 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $168,512 66 payments
  2. Novo Nordisk AS $165,861 45 payments
  3. Eli Lilly and Company $155,650 101 payments
  4. Boehringer Ingelheim International GmbH $86,015 63 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $61,693 45 payments
  6. Merck Sharp & Dohme Corporation $55,362 39 payments
  7. Intercept Pharmaceuticals, Inc. $47,402 5 payments
  8. Sanofi-Aventis U.S. LLC $45,585 18 payments
  9. Boehringer Ingelheim b.v. $44,503 5 payments
  10. Pfizer Inc. $41,340 12 payments
  11. Other $318,637 133 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $910,035 215 payments
  2. Travel and Lodging $163,327 150 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $95,402 31 payments
  4. Honoraria $12,800 4 payments
  5. Food and Beverage $8,996 132 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $138,461 69 payments
  2. TRADJENTA $50,107 17 payments
  3. SOTAGLIFLOZIN $37,077 11 payments
  4. Victoza $31,394 12 payments
  5. JARDIANCE Diabetes $25,145 11 payments
  6. SOLIQUA 100/33 $18,039 8 payments
  7. FARXIGA $15,918 13 payments
  8. STEGLATRO Endocrinology $15,105 19 payments
  9. Heplisav-B $11,750 10 payments
  10. STEGLATRO Cardiovascular $9,309 2 payments
  11. Other $51,250 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk AS $146,621 27 payments
  2. Pfizer Inc. $57,030 54 payments
  3. Eli Lilly and Company $19,213 2 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $9,000 4 payments
  5. Akebia Therapeutics Inc $6,480 3 payments
  6. Amgen Inc. $6,371 1 payment
  7. AbbVie, Inc. $2,400 1 payment

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$6,494

Medicare's payments for the services billed

Medicare patients

68

Average age 67

Services billed

87

31 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 69%
Diabetes 68%
Chronic kidney disease 53%
Arthritis 40%
COPD 28%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Eli Lilly and Company $9,545
  • Boehringer Ingelheim Pharmaceuticals, Inc. $630
$10,175 — —
MOUNJARO
  • Eli Lilly and Company $5,691
$5,691 — —
FARXIGA
  • AstraZeneca UK Limited $500
$500 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

624 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record